OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

June 1st 2022

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Cusnir on the Utilization of Y-90 Maintenance in CRC

June 1st 2022

Mike Cusnir, MD, discusses the utilization of SIR-Spheres® Y-90 resin microspheres as maintenance therapy in colorectal cancer.

Dr. Sallman on the Novel Menin Inhibitor KO-539 in AML

May 31st 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

Dr. Yang on the Current Treatment Landscape in MCL

May 26th 2022

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

May 26th 2022

Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.

Dr. Goel on the Need for Diverse Representation in Clinical Trials

May 26th 2022

Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

May 26th 2022

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRC

May 25th 2022

Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.

Dr. Packiam the Investigation of Cabazitaxel Plus Gemcitabine with Pembrolizumab in Urothelial Carcinoma

May 25th 2022

Vignesh Packiam, MD, discusses the investigation of cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Raje on Unmet Needs with CAR T-Cell Therapy in Myeloma

May 25th 2022

Noopur Raje, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

May 24th 2022

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Shaukat on the Methods Utilized in the PREEMPT-CRC Trial in CRC

May 24th 2022

Aasma Shaukat, MD, MPH, discusses the methods utilized in the PREEMPT CRC trial in colorectal cancer.

Dr. O’Donnell on the Ideal Patients for CAR T-Cell Therapies

May 23rd 2022

Betsy O'Donnell, MD, discusses the ideal patients for CAR T-cell therapies in multiple myeloma.

Dr. Lee on the Importance of Collaboration in Precision Medicine

May 23rd 2022

Kelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

May 23rd 2022

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Dr. Ailawadhi on the Examination of Iopofosine I-131 in Waldenström Macroglobulinemia

May 20th 2022

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

May 20th 2022

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

May 20th 2022

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

May 20th 2022

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.